

1 **A novel role for cilia function in atopy: *ADGRVI* and *DNAH5* interactions**

2  
3 Pierre-Emmanuel Sugier<sup>a,b</sup>, MSc, Myriam Brossard<sup>a\*</sup>, PhD, Chloé Sarnowski<sup>a\*</sup>, PhD, Amaury  
4 Vaysse<sup>a</sup>, PhD, Andréanne Morin<sup>c,d</sup>, MSc, Lucile Pain<sup>d</sup>, MSc, Patricia Margaritte-Jeannin<sup>a</sup>, PhD,  
5 Marie-Hélène Dizier<sup>a</sup>, PhD, William O.C.M. Cookson, MD, D.Phil.<sup>e</sup>, Mark Lathrop<sup>c</sup>, PhD, Miriam  
6 F. Moffatt, D.Phil.<sup>e</sup>, Catherine Laprise<sup>d‡</sup>, PhD, Florence Demenais<sup>a‡</sup>, MD, Emmanuelle  
7 Bouzigon<sup>a‡</sup>, MD, PhD

8  
9 \*These authors shared second authorship.

10 ‡These authors shared senior authorship.

11 <sup>a</sup>Genetic Variation and Human Diseases Unit, INSERM, Université Paris Diderot, Université  
12 Sorbonne Paris Cité, Paris, France

13 <sup>b</sup>Université Pierre et Marie Curie, Paris, France

14 <sup>c</sup>McGill University and Génome Québec Innovation Centre, Montréal, Canada

15 <sup>d</sup>Département des Sciences Fondamentales, Université du Québec à Chicoutimi, Chicoutimi, QC,  
16 Canada

17 <sup>e</sup>Section of Genomic Medicine, National Heart and Lung Institute, London, UK

18 **Correspondance:**

19 Florence Demenais, MD

20 UMR-946, INSERM, Université Paris-Diderot

21 27 rue Juliette Dodu

22 75010 Paris

23 Tel: 33 (0) 1 53 72 50 02

24 Fax: 33 (0) 1 53 72 50 49

25 Email: florence.demenais@inserm.fr

26 **Disclosure of potential conflict of interest:** all authors declare no conflict of interest

27

28 **Sources of support:** This work was supported by the French National Agency for Research (ANR-  
29 11-BSV1-027-GWIS-AM; ANR-USPC-2013-EDAGWAS) and Université Pierre et Marie Curie  
30 doctoral fellowship, The Canada Research Chair held by C Laprise and the funding supports from  
31 Canadian Institutes of Health Research (CIHR) enabled the maintenance and continuation of the  
32 SLSJ asthma study. C. Laprise is the director of the Asthma Strategic Group of the Respiratory  
33 Health Network of the Fonds de la recherche en santé du Québec (FRSQ) and member of Allergen  
34 network. Genotyping was supported by grants from the European Commission (No. LSHB-CT-  
35 2006-018996-GABRIEL).

36

37 Manuscript count: 3809

38 Abstract count: 248

39

40 **ABSTRACT**

41 **Background:** Atopy, an endotype underlying allergic diseases, has a substantial genetic  
42 component.

43 **Objective:** Our goal was to identify novel genes associated with atopy in asthma-ascertained  
44 families.

45 **Methods:** We implemented a three-step analysis strategy in three datasets: The Epidemiological  
46 study on the Genetics and Environment of Asthma (EGEA) dataset: 1,660 subjects; The Saguenay-  
47 Lac-Saint-Jean (SLSJ) dataset: 1,138 subjects; and The Medical Research Council (MRC) dataset:  
48 446 subjects). This strategy included a single-SNP genome-wide association study (GWAS), the  
49 selection of related gene pairs based on statistical filtering of GWAS results and text-mining  
50 filtering using GRAIL and SNP-SNP interaction analysis of selected gene pairs.

51 **Results:** We identified the 5q14 locus, harboring the adhesion G protein-coupled receptor V1  
52 (*ADGRV1*) gene, that showed genome-wide significant association with atopy (rs4916831;  
53  $P_{\text{meta}}=6.8 \times 10^{-9}$ ). Statistical filtering of GWAS results followed by text-mining filtering revealed  
54 relationships between *ADGRV1* and three genes showing suggestive association with atopy ( $P \leq 10^{-4}$ ).  
55 SNP-SNP interaction analysis between *ADGRV1* and these three genes showed significant  
56 interaction between *ADGRV1* rs17554723 and two correlated SNPs (rs2134256 and rs1354187)  
57 within dynein axonemal heavy chain 5 (*DNAH5*) gene ( $P_{\text{meta-int}}=3.6 \times 10^{-5}$  and  $6.1 \times 10^{-5}$ , that met the  
58 multiple-testing corrected threshold of  $7.3 \times 10^{-5}$ ). Further conditional analysis indicated that  
59 rs2134256 alone accounted for the interaction signal with rs17554723.

60 **Conclusion:** As both *DNAH5* and *ADGRV1* contribute to function of cilia, this study suggests that  
61 cilia dysfunction may represent a novel mechanism underlying atopy. Combining GWAS and  
62 epistasis analysis driven by statistical and knowledge-based evidence represents a promising  
63 approach for identifying new genes involved in complex traits.

64 **Key Messages:**

- 65 • *ADGRVI* genetic variants are associated with atopy in asthma families
- 66 • Interaction between *ADGRVI* and *DNAH5* variants is associated with atopy; these two
- 67 genes are involved in ciliary function
- 68 • Use of a strategy that combines genome-wide association analysis and epistasis analysis
- 69 driven by statistical and knowledge-based evidence can successfully identify new genes
- 70 underlying complex traits.

71 **Capsule summary:**

72 This study in three family-based studies identified association between *ADGRVI* and atopy and

73 interaction between *ADGRVI* and *DNAH5*, two genes that contribute to ciliary functions.

74 **Key words:** atopy, asthma, genetics, genome-wide association study, gene-gene interaction, text-

75 mining, *ADGRVI*, *DNAH5*, ciliary function

76 **Abbreviations:**

77 *ADGRVI*: adhesion G protein-coupled receptor V1

78 *DNAH5*: dynein, axonemal, heavy chain 5

79 SNP: single nucleotide polymorphism

80 GWAS: genome-wide association study

81 SPT: skin prick test

82 EGEA: Epidemiological study on the Genetics and Environment of Asthma

83 SLSJ: Saguenay-Lac-Saint-Jean study

84 MRCA: Medical Research Council funded collection of nuclear families with Asthma

85 MRCE: Medical Research Council funded collection of nuclear families with Eczema

- 86 GRAIL: Gene Relationships Across Implicated Loci
- 87 QC: quality control
- 88 MAF: minor allele frequency
- 89 PCs: principal components
- 90 LD: linkage disequilibrium
- 91 ORs: odds-ratios
- 92 GTEx: Genotype-Tissue Expression
- 93 ETS: environmental tobacco smoke
- 94 CI: confidence interval
- 95

96 **INTRODUCTION**

97 Allergies and asthma are among the most common diseases in industrialized countries. Although  
98 environmental factors play an important role in allergic diseases, estimates of heritability of allergy,  
99 which range between 25% and 80%, suggest significant genetic contribution.<sup>1</sup> Genome-wide  
100 association studies (GWAS) have identified a number of loci associated with allergic diseases (i.e.,  
101 asthma, atopic dermatitis, rhinitis),<sup>2,3</sup> but these loci only explain a small part of the genetic risk.  
102 Part of the difficulty encountered in identifying the genetic factors involved in these allergic  
103 diseases is due to the heterogeneity of these diseases and the uncertainty of diagnosis. However,  
104 this problem can be alleviated by the study of an endotype underlying allergic diseases, such as  
105 allergic sensitization or atopy.

106 Atopy is characterized by the production of allergen-specific immunoglobulin E against  
107 environmental allergens. Estimates of heritability of atopy range from 40% to 85%.<sup>4,5</sup> Many  
108 candidate genetic studies of atopy have been conducted but have often led to inconsistent results.<sup>6</sup>  
109 While the first GWAS of allergic sensitization only reported a few loci,<sup>7-10</sup> two recent large-scale  
110 meta-analyses of allergic sensitization<sup>11</sup> and self-reported allergy<sup>12</sup> increased the number of  
111 associated loci to 10 and 16 loci, respectively. However, other loci may influence atopy as it is well  
112 known that GWAS alone cannot reveal the whole genetic landscape underlying complex  
113 phenotypes.

114 Heterogeneity across studies, which may be caused by variability in the genetic background of the  
115 populations, environmental exposures, or study design, may be a limitation of meta-analyses of  
116 GWAS for identifying new loci associated with a trait. Notably, the importance of data sampling  
117 was recently highlighted by a positional cloning study of eczema, where association with  
118 *ANO3/MUC15* genetic variants was only found in family samples ascertained through asthmatic

119 subjects but neither in families ascertained through eczema patients nor in a case/control study of  
120 eczema.<sup>13</sup>

121 Another limitation of GWAS is that they typically focus on the analysis of individual single  
122 nucleotide polymorphisms (SNPs) and are underpowered to detect genetic factors which have a  
123 small marginal effect but rather interact with each other. Gene-gene interaction analysis (or  
124 epistasis analysis) has the ability to reveal novel genes involved in complex traits but raises an  
125 enormous multiple-testing problem when performed at the genome-wide level. Statistical and  
126 biological filtering pipelines can be used to limit the search for SNP-SNP interactions.<sup>14</sup> Following  
127 the “guilt-by-association” assumption which states connected genes are usually participating in the  
128 same or related cellular functions,<sup>15</sup> search for interactions can be restricted to genes pointed out  
129 by a preliminary GWAS (e.g., interactions of genes harboring significant association signals with  
130 genes harboring suggestive associations) and showing relationships based on prior knowledge. One  
131 knowledge-based approach that can be particularly useful to prioritize genes for epistasis analysis  
132 is text-mining of the literature as it can highlight relationships between genes<sup>16</sup> according to their  
133 co-occurrence with the same words in scientific articles.

134  
135 The objective of this study was to identify novel genetic factors influencing atopy by combining a  
136 GWAS and epistasis analysis driven by statistical and knowledge-based evidence in three family  
137 samples ascertained through asthmatic subjects: the French Epidemiological study on the Genetics  
138 and Environment of Asthma (EGEA; 1,660 subjects), the French-Canadian Saguenay-Lac-Saint-  
139 Jean study (SLSJ; 1,138 subjects) and the Medical Research Council UK study (MRC; 446  
140 subjects). Our overall analysis strategy included three main steps: (1) a genome-wide single-SNP  
141 association analysis, (2) the selection of related gene pairs based on statistical filtering from GWAS

142 results and text-mining filtering using the Gene Relationships Across Implicated Loci (GRAIL)  
143 approach,<sup>17</sup> and (3) a SNP-SNP interaction analysis for the selected gene pairs.

144

## 145 **MATERIALS AND METHODS**

### 146 *Study datasets and definition of atopy*

147 The EGEA study combines a case-control and a family-based study of asthma. The whole study  
148 population includes 388 families ascertained through at least one asthmatic proband recruited in  
149 chest clinics (1,705 probands and first-degree relatives) plus 415 population-based controls (total  
150 of 2,120 subjects). All subjects were born in France and were of European ancestry. The protocol  
151 of this study has been described elsewhere.<sup>18-20</sup> Atopy was assessed by skin prick tests (SPT)  
152 performed in 1,978 subjects. A positive SPT response was defined as a wheal diameter  $\geq$  3mm to  
153 at least one of 11 aeroallergens belonging to three groups (indoor allergens, outdoor allergens,  
154 molds). After quality control (QC) of genotypic data, 925 atopic and 735 non-atopic subjects were  
155 included in the analysis.

156 The Saguenay-Lac-Saint-Jean and Quebec City Familial Asthma Collection (SLSJ) consists of a  
157 French-Canadian founder population panel of 253 multigenerational families from Saguenay-Lac-  
158 Saint-Jean region, ascertained through two asthmatic probands.<sup>21</sup> This study has been described  
159 elsewhere.<sup>21</sup> Skin tests were done in 1,195 SLSJ subjects and atopy was defined similarly as in  
160 EGEA. After QC of genotypic data, the analysis dataset included 641 atopic and 497 non-atopic  
161 subjects.

162 The Medical Research Council (MRC) UK study includes 207 nuclear families, recruited through  
163 at least one proband with childhood-onset asthma (MRCA sample). The study protocol has been  
164 described elsewhere.<sup>22</sup> Atopy was defined similarly as in EGEA. To increase the number of  
165 unaffected subjects (controls), we included subjects from another MRC-UK dataset that were



166 recruited through probands with eczema (MRCE sample). Only subjects without asthma, without  
167 eczema and with low IgE levels were used as controls in this study. We checked that the age and  
168 gender distributions were similar in MRCA and MRCE samples. After QC of genotypic data, the  
169 analysis sample included 106 atopic and 340 non-atopic subjects. The whole UK sample will be  
170 subsequently designated as the MRC sample.

171 Protocols of EGEA, SLSJ and MRC studies have been approved by the local ethical committees.  
172 All adult participants and child's legal guardians provided written informed consent.

173

#### 174 *Genotyping*

175 Both EGEA and SLSJ datasets were genotyped using the Illumina 610-Quad array (Illumina, San  
176 Diego, CA), as part as of the Gabriel asthma consortium GWAS.<sup>23</sup> Stringent quality criteria were  
177 applied to select both individuals and SNPs and have been previously detailed.<sup>23,24</sup> After QC, there  
178 was a final set of 501,167 autosomal SNPs for analysis. The offspring in MRCA families and  
179 MRCE controls were genotyped using the Illumina Sentrix HumanHap300 BeadChip (307,981  
180 autosomal SNPs), as part of the first asthma GWAS.<sup>22,23</sup> QC for MRC samples has been detailed  
181 elsewhere.<sup>22,25</sup> In order to get a number of SNPs in MRC sample as large as in EGEA and SLSJ  
182 samples, SNP imputation was performed using MACH v1.00 software<sup>26</sup> and HapMap2 release 21  
183 CEU haplotypes as reference panel. Imputed SNPs were kept for analysis if their imputation quality  
184 score (rsq)<sup>27</sup> was  $\geq 0.5$  and minor allele frequency was  $\geq 5\%$ .

185

#### 186 *Descriptive statistics and strategy of analysis*

187 Descriptive statistics of atopy together with sex, age and asthma status were assessed in each  
188 dataset using Stata® V14.1 (distributed by Stata Corporation, College Station, Texas, USA). The

189 workflow of our three-step analysis strategy is summarized in Figure 1 and presented in the  
190 following paragraphs.

191

### 192 ***Genome-wide single-SNP analysis***

193 We performed a two-stage GWAS. In the first stage, association analysis between individual SNPs  
194 and atopy was carried out in the EGEA dataset. This analysis was based on a logistic regression  
195 model assuming an additive model for SNP effect, using Stata® V14.1. This model was adjusted  
196 for significant effects of age and sex and two principal components (PCs) to account for population  
197 structure. We took into account familial dependencies using the cluster and robust options of the  
198 logit function in Stata®. Test of SNP effect was based on a Wald-test. In a second stage, the SNPs  
199 reaching  $P \leq 10^{-4}$  in EGEA were followed-up in SLSJ and MRC. The association analysis in SLSJ  
200 and in MRC used the same model as in EGEA. The results of stage 2 datasets and, then, of the  
201 three datasets were combined using a fixed-effects meta-analysis. SNPs were declared significantly  
202 associated with atopy if the three datasets meta-analysis  $P$ -value ( $P_{\text{meta}}$ ) reached the genome-wide  
203 significance level of  $1.5 \times 10^{-7}$ . This threshold was obtained by dividing the type I error of 5% by  
204 the effective number of independent SNPs in the Illumina 610-Quad array.<sup>28</sup>

205

### 206 ***Selection of gene pairs using both statistical and text-mining filters***

207 The statistical filtering consisted of selecting two sets of genes using the GWAS results: genes  
208 showing significant association with atopy (set-1) and genes showing suggestive association with  
209 atopy (set-2). The set-1 included all genes lying at a distance of 50 kb or less from SNPs reaching  
210 the genome-wide significance level in the GWAS meta-analysis. The set-2 included all genes that  
211 were at most 50 kb apart from SNPs having  $P \leq 10^{-4}$  in the stage 1 EGEA dataset and were not part

212 of set-1. To assign SNPs to genes, we used NCBI dbSNP Build 137 and human Genome Build  
213 37.3. We further filtered gene pairs (formed by crossing set-1 genes with set-2 genes) through  
214 GRAIL<sup>17</sup> text-mining of PubMed abstracts (available in October 2014). For each gene, GRAIL  
215 builds a vector of words where the elements of this vector are weights that take values between 0  
216 and 1 depending on how often a word is found with a gene in an abstract. Then, GRAIL computes  
217 pairwise similarity between genes from gene/word vectors and ranks the similarities between each  
218 gene from set-1 and all genes of the genome. The  $P_{\text{GRAIL}}$  of a gene from set-2 with a gene from set-  
219 1 is equal to the proportion of all genes that have similarity with the set-1 gene greater than the  
220 similarity between set-2 and set-1 genes (i.e. rank divided by total number of genes across the  
221 genome). We used the threshold of  $P_{\text{GRAIL}} \leq 0.10$ , as recommended,<sup>17</sup> to select related gene pairs  
222 for further epistasis analysis.

223

#### 224 *SNP-SNP interaction analysis for selected gene pairs*

225 As for the single-SNP association analysis, we performed a two-stage SNP-SNP interaction  
226 analysis. At stage 1, we analyzed all SNP-SNP interactions for the GRAIL-selected gene pairs in  
227 the EGEA dataset. For each gene, we considered all SNPs lying within gene boundaries. Pairwise  
228 SNP-SNP interactions were evaluated by logistic regression assuming an additive model for SNP  
229 main effects and interaction and adjusting for the same covariates (age, sex, PCs) as in the GWAS,  
230 using Stata® V14.1. We used the same coding scheme as usually proposed for SNP-SNP  
231 interaction modelling.<sup>29</sup> We modeled the additive effect of a SNP by coding the genotypes of  
232 homozygotes for the minor allele, heterozygotes and homozygotes for the major allele as 1, 0, and  
233 -1; the interaction term between two SNPs was obtained by multiplication of these genotypic values  
234 for the two SNPs. Test of interaction was based on a likelihood-ratio test which follows a Chi-  
235 square distribution with one degree of freedom. We discarded all SNP pairs for which one or more

236 of the nine genotypic combinations appeared in fewer than five subjects (cases or controls). In a  
237 second stage, all SNP pairs showing suggestive evidence for interaction in EGEA ( $P_{\text{int}} \leq 5 \times 10^{-3}$ )  
238 were followed-up in SLSJ and MRC. The results of the stage 2 datasets and, then, of the three  
239 datasets were meta-analyzed using a fixed-effects model.

240 To correct for multiple testing, we computed, for each gene pair investigated, the effective number  
241 of independent interaction tests from the eigenvalues of the correlation matrix of products of SNP  
242 variables, using an extension of Li and Ji's method.<sup>30</sup> The corrected threshold to declare an  
243 interaction statistically significant was equal to the 5% type I error divided by the sum of effective  
244 number of independent interaction tests over all gene pairs tested.

245

#### 246 **Stratified analyses according to asthma status**

247 Because family samples were ascertained through asthmatic probands, we investigated whether  
248 SNP associations and SNP-SNP interactions detected with atopy might be related to the presence  
249 of asthma. Single-SNP and SNP-SNP interaction analyses were repeated in the two groups of  
250 asthmatic and non-asthmatic subjects separately. These analyses were performed for the SNPs that  
251 showed significant results in the meta-analyses of the three datasets. Homogeneity of the odds-  
252 ratios (ORs) between the two groups was tested using the Cochran's Q statistic.<sup>31</sup>

253

254

## 255 **RESULTS**

### 256 *Descriptive statistics*

257 A total of 1,660 EGEA, 1,138 SLSJ and 446 MRC subjects were included in this study. The  
258 proportion of atopic subjects was similar in EGEA and SLSJ (55.7% and 56.3% respectively) but  
259 was lower in MRC (23.8%;  $P \leq 10^{-3}$ ). In each study, there was a higher proportion of males in atopic

260 than in non-atopic subjects and atopic subjects were younger than non-atopic subjects (see Table  
261 E1 in the Online Repository). As expected, the proportion of asthmatic subjects was higher in  
262 atopic than in non-atopic subjects in all datasets (Table E1). In EGEA (respectively in SLSJ and  
263 MRC), 78.0% (75.0% and 78.3%) of atopic subjects had positive SPT to indoor allergens, 55.5%  
264 (77.5% and 52.8%) to outdoor allergens, and 34.8% (14.8% and 12.3%) to molds.

265

### 266 ***Genome-wide single-SNP analysis***

267 In the stage 1 EGEA dataset, no SNP reached the genome-wide significance level of  $1.5 \times 10^{-7}$  (see  
268 quantile-quantile (QQ) plot and Manhattan plot in Figures E1 and E2). However, 73 SNPs lying in  
269 47 loci showed associations with atopy exceeding the screening threshold of  $P \leq 10^{-4}$ . These SNPs  
270 were followed-up in the stage 2 SLSJ and MRC datasets and meta-analyzed (Table E2). The SNP  
271 rs4916831 within *ADGRV1* gene at 5q14 reached the genome-wide significance level  
272 ( $P_{\text{meta}} = 6.8 \times 10^{-9}$ ) in the overall meta-analysis of the three datasets (Table I). Four other SNPs at that  
273 locus, in moderate linkage disequilibrium (LD) with rs4916831 ( $r^2$  ranging between 0.51 and 0.79),  
274 showed suggestive association ( $4.3 \times 10^{-7} \leq P_{\text{meta}} \leq 3.8 \times 10^{-6}$ ; Table I).

275

### 276 ***Selection of gene pairs using both statistical and text-mining filters***

277 The gene set-1 included *ADGRV1*, the only gene significantly associated with atopy. There were  
278 30 genes that lied fewer than 50 kb apart from the 65 SNPs at 46 loci having  $P \leq 10^{-4}$  in EGEA (after  
279 exclusion of *ADGRV1* SNPs) and formed gene set-2 (Table E3). When GRAIL was applied to 30  
280 gene pairs (date accessed: 04/24/2015), formed by each of these 30 genes with *ADGRV1*, three  
281 genes were related with *ADGRV1* at  $P_{\text{GRAIL}} < 0.10$ : *DNAH5* on 5p15 ( $P_{\text{GRAIL}} = 0.084$ ), *CHD7* on 8q12  
282 ( $P_{\text{GRAIL}} = 3.2 \times 10^{-3}$ ) and *ATP8B1* on 18q21 ( $P_{\text{GRAIL}} = 0.016$ ).

283

284 ***SNP-SNP interaction analysis for selected gene pairs***

285 In the stage 1 EGEA dataset, the three GRAIL-selected gene-pairs (*ADGRVI/DNAH5*,  
286 *ADGRVI/CHD7*, *ADGRVI/ATP8B1*) were each examined for SNP-SNP interactions, making a  
287 total of 5,324 SNP pairs. There were 37 SNP pairs that reached  $P_{\text{int}} \leq 5 \times 10^{-3}$  in EGEA and were  
288 followed-up in SLSJ and MRC at stage 2. Two of these SNPs pairs, which are related to the  
289 *ADGRVI* and *DNAH5* gene pair, met the multiple-testing corrected threshold, estimated to be  
290  $7.3 \times 10^{-5}$  (see Table E4), in the meta-analysis of the three datasets (Table II). The two significant  
291 interactions involved the same SNP rs17554723 within *ADGRVI* and two SNPs within *DNAH5*,  
292 rs2134256 ( $P_{\text{meta-int}} = 3.6 \times 10^{-5}$ ) and rs1354187 ( $P_{\text{meta-int}} = 6.1 \times 10^{-5}$ ), that are in moderate LD ( $r^2 = 0.50$ ;  
293  $D' = 0.95$ ). However, further conditional regression analysis in each of the strata defined by  
294 genotypes at *ADGRVI* rs17554723 showed that *DNAH5* rs1354187 was no longer significantly  
295 associated with atopy ( $P \geq 0.15$ ) when conditioning on *DNAH5* rs2134256. The most significant  
296 SNP pair shows a pattern of interaction in which the ORs for atopy associated with TT (or CC)  
297 genotype at *DNAH5* rs2134256 are in opposite direction according to the genotype, AA (or GG),  
298 at *ADGRVI* rs17554723 (Figure 2). This pattern was consistent in all three datasets (Figure 2).

299

300 **Stratified analyses according to asthma status**

301 Association analyses of atopy with the genome-wide significant *ADGRVI* rs4916831 SNP in  
302 asthmatic and non-asthmatic subjects did not show any relationship with presence of asthma in the  
303 stage 1 and stage 2 datasets and meta-analysis of the three datasets ( $P_{\text{Cochran}}$  for test of homogeneity  
304 between the two groups  $\geq 0.82$ ; Table E5A). In the meta-analysis, the evidence for association was  
305 even stronger although not significantly in non-asthmatics ( $P = 7.8 \times 10^{-6}$ ) than in asthmatics  
306 ( $P = 1.4 \times 10^{-4}$ ). Similarly, interaction analyses for *ADGRVI* and *DNAH5* SNPs did not show any  
307 relationship with asthma ( $P_{\text{Cochran}} \geq 0.30$ ; Table E5B). The evidence for interaction was only

308 significant in non-asthmatic subjects (Table E6B); this can be at least partly explained by the larger  
309 sample size of non-asthmatic (N=1,849) than asthmatic subjects (N=1,354).

310

### 311 **Functional annotations of SNPs showing significant results**

312 All SNPs that show significant association (or interaction) with atopy are intronic. The two  
313 *ADGRV1* SNPs, rs4916831 and rs17554723 on 5q14, detected through GWAS and interaction  
314 analysis, lie 120 kb apart in introns 83 (rs4916831) and 70 (rs17554723) and are in low LD  
315 ( $r^2=0.20$ ,  $D'=0.75$ ). The two *DNAH5* SNPs (rs2134256 and rs1354187) at 5p15.2 are located in  
316 introns 58 and 60 (8 kb apart) but only rs2134256 accounts for the interaction signal (see above).  
317 By interrogating the Genotype-Tissue Expression (GTEx) database,<sup>32</sup> rs4916831 was found  
318 associated with *ADGRV1* expression in esophagus mucosa ( $P=7.5 \times 10^{-7}$ ).<sup>32</sup> We also investigated  
319 whether the *ADGRV1* and *DNAH5* SNPs (as well as their proxies,  $r^2 \geq 0.80$ ) map to functionally  
320 important regulatory regions using HaploRegV4.<sup>33</sup> As shown in Table E6, these SNPs and/or  
321 proxies map to binding sites of various transcription factors (TFs). In addition, four proxies of  
322 *ADGRV1* rs4916831 map to enhancer histone marks in lung and skin while a proxy of *DNAH5*  
323 rs2134256 maps to promoter and enhancer marks in hematopoietic stem cells.

324

### 325 **DISCUSSION**

326 By combining genome-wide single-SNP analysis and epistasis analysis driven by statistical and  
327 knowledge-based evidence in three asthma-ascertained family datasets, we identified significant  
328 association of atopy at a novel 5q14 locus harboring *ADGRV1* gene and significant interaction  
329 between *ADGRV1* and *DNAH5* genetic variants.

330 The interaction between *ADGRV1* and *DNAH5* variants has biological relevance as these two genes  
331 are both involved in ciliopathies and ciliary function. Ciliopathies comprise a group of disorders

332 associated with genetic mutations encoding defective proteins, which result in either abnormal  
333 formation or function of cilia.<sup>34</sup> Mutations in the adhesion G protein-coupled receptor V1  
334 (*ADGRV1*) gene cause Usher syndrome type IIC, a ciliopathy characterized by hearing loss and  
335 visual impairment,<sup>35,36</sup> while mutations of dynein axonemal heavy chain 5 (*DNAH5*) gene cause  
336 primary ciliary dyskinesia type 3, a ciliopathy which combines upper and lower tract respiratory  
337 manifestations, male infertility, and situs inversus.<sup>37</sup> The ADGRV1 protein (also called GPR98) is  
338 a component of the Usher protein network that functions in stereocilia of inner ear hair cells and  
339 photoreceptor cilia. The heavy chain of axonemal dynein, encoded by *DNAH5*, is part of a  
340 microtubule-associated motor protein complex that is responsible for cilia mobility, especially in  
341 respiratory epithelial cells where cilia motility is essential for mucus transport and airway  
342 clearance.<sup>38</sup> Although the respective function of ADGRV1 and *DNAH5* proteins was initially  
343 described in different organs, these proteins may also have related functions. Indeed, the cilium in  
344 photoreceptors is ultrastructurally very similar to the nasal ciliated epithelium and the nasal ciliated  
345 epithelium of Usher syndrome II patients was found to have a lower ciliary beat frequency than  
346 healthy controls.<sup>39</sup> Moreover, Usher syndrome has been reported to be associated with  
347 bronchiectasis, sinusitis and reduced nasal mucociliary clearance.<sup>40</sup>

348 Besides the involvement of both ADGRV1 and *DNAH5* proteins in cilia functions, which supports  
349 the statistical interaction found between these two genes, both *DNAH5* and *ADGRV1* genes have  
350 been previously associated with respiratory diseases and related phenotypes. Recent GWAS  
351 reported significant association of *DNAH5* variants with total lung capacity in chronic obstructive  
352 pulmonary disease<sup>41</sup> and suggestive association with Immunoglobuline E grass sensitization.<sup>9</sup>  
353 However, the SNP reported by that latter study was not in LD with the *DNAH5* SNPs interacting  
354 with *ADGRV1* SNP in this study ( $r^2 < 0.13$ ). Based on an approach similar to ours, which combined  
355 genome-wide expression data in nasal epithelial cells, allele frequency variation between



356 populations and literature search to select candidate genes, nominal association of asthma with  
357 *DNAH5* was reported and stronger association was found with *KIF3*, a gene involved in transport  
358 of protein complexes within cilia and potentially in allergen clearance as *DNAH5*.<sup>42</sup> In addition,  
359 *DNAH5* belongs to the same gene family as *DNAH9* which showed interaction with environmental  
360 tobacco smoke (ETS) exposure for bronchial hyperresponsiveness in EGEA and SLSJ families.<sup>43</sup>  
361 Moreover, suggestive association of *ADGRV1* with asthma has been recently reported by a meta-  
362 analysis of GWAS.<sup>44</sup> Though most previously reported associations concern asthma or respiratory  
363 phenotypes, the interaction between *ADGRV1* and *DNAH5* SNPs associated with atopy in the  
364 present study appears independent of asthma, as shown by the stratified analysis on asthma.  
365 Although the mechanism by which these two genes influence atopy is still unknown, we can  
366 hypothesize that they are involved in dysfunction of cilia that move secreted mucus containing  
367 trapped foreign particles up and out of the airways, which favors allergic sensitization. This is  
368 supported by recent observations of a differential mRNA expression of both *ADGRV1* and *DNAH5*  
369 genes in sputum from House Dust Mite (HDM)-sensitized wheezing subjects as compared to non-  
370 atopic controls.<sup>45</sup> Furthermore, *DNAH5* as well as other genes of the same family including *DNAH9*  
371 were among the highest-ranking co-expression hubs in one of the HDM-wheezing associated gene  
372 modules, which was strongly enriched with genes involved in the function of ciliated epithelial  
373 cells.<sup>45</sup> All these observations suggest cilia-related genes may constitute an important emerging  
374 pathway for atopy.

375 The strategy used in this study, that enabled identifying novel relevant candidates for atopy,  
376 combined genome-wide single-SNP analysis and gene-gene interaction analysis based on both  
377 statistical filtering of GWAS results and text-mining filtering. It is of note that our three-step  
378 strategy was designed *a priori* and SNP-SNP interaction tests were only performed for gene pairs  
379 selected through our two filtering processes. The genome-wide single-SNP analysis pointed

380 towards one gene (*ADGRVI*) which harbored the lead SNP rs4916831 reaching genome-wide  
381 significance and four other SNPs showing suggestive association. By increasing the density of  
382 SNPs through Hapmap2-based imputation at that locus, an additional SNP ( $r^2=0.80$  with  
383 rs4916831) reached genome-wide significance and six other SNPs had P-values within one order  
384 of magnitude of the genome-wide threshold (results not shown), which strengthens our finding.  
385 Further conditional analysis in that region showed that association with atopy was only accounted  
386 for by the lead genotyped SNP. The subsequent statistical and text-mining filters, used prior to  
387 epistasis analysis, made it possible to detect gene-gene interaction by lowering the multiple testing  
388 burden. Indeed, use of both filters reduced the number of interaction tests by 9-fold as compared  
389 to using the statistical filter only. The text-mining filter was based on GRAIL that was shown to be  
390 successful in pointing out true disease regions that were validated.<sup>17</sup> Although many sources of  
391 biological information can be used to connect genes, such as co-expression gene networks or  
392 protein-protein interaction networks, the advantage of GRAIL is to provide a broader framework  
393 for revealing gene-gene relationships of any origin through literature search. However, GWAS and  
394 candidate gene studies, which are driven by researchers' expectations, can create a bias towards  
395 genes that are frequently reported in the literature. An appropriate approach would be to utilize the  
396 existing knowledge and to correct for potential bias but, to our knowledge, such method does not  
397 exist yet.

398  
399 In conclusion, this study shows that the proposed strategy that combines GWAS and epistasis  
400 analysis driven by statistical and knowledge-based evidence can successfully identify strong  
401 candidate genes for complex phenotypes as atopy. The interaction between *DNAH5* and *ADGRVI*,  
402 two genes involved in cilia functions, is of biological relevance and provides a novel mechanism

403 underlying atopy. Further studies, including functional and experimental studies, are needed to  
404 confirm the current findings and to identify the functional variants.

405

406 **Acknowledgments**

407 EGEA: The authors thank all those who participated to the setting of the study and on the various  
408 aspects of the examinations involved: interviewers, technicians for lung function testing and skin  
409 prick tests, blood sampling, IgE determinations, coders, those involved in quality control, data and  
410 sample management and all those who supervised the study in all EGEA centers. The authors are  
411 grateful to the three CIC-Inserm of Necker, Grenoble and Marseille who supported the EGEA study  
412 and in which subjects were examined. They are also grateful to the biobanks in Lille (CIC-Inserm)  
413 and at Annemasse (Etablissement français du sang) where EGEA biological samples are stored.  
414 We thank the Epidemiological Study on Genetics and Environment of Asthma (EGEA) cooperative  
415 group members as follows.

416 Coordination: V Siroux (epidemiology, PI since 2013); F Demenais (genetics); I Pin (clinical  
417 aspects); R Nadif (biology). F Kauffmann (PI 1992-2012); Respiratory epidemiology: Inserm U  
418 700, Paris M Korobaëff (Egea1), F Neukirch (Egea1); Inserm U 707, Paris: I Annesi-Maesano  
419 (Egea1-2); Inserm CESP/U 1018, Villejuif: F Kauffmann, N Le Moual, R Nadif, MP Oryszczyn  
420 (Egea1-2), R. Varraso; Inserm U 823, Grenoble: V Siroux. Genetics: Inserm U 393, Paris: J  
421 Feingold; Inserm U 946, Paris: E Bouzigon, F Demenais, MH Dizier; CNG, Evry: I Gut (now  
422 CNAG, Barcelone, Spain), M Lathrop (now Univ McGill, Montreal, Canada). Clinical centers:  
423 Grenoble: I Pin, C Pison; Lyon: D Ecochard (Egea1), F Gormand, Y Pacheco; Marseille: D Charpin  
424 (Egea1), D Vervloet (Egea1-2); Montpellier: J Bousquet; Paris Cochin: A Lockhart (Egea1), R  
425 Matran (now in Lille); Paris Necker: E Paty (Egea1-2), P Scheinmann (Egea1-2); Paris-Trousseau:  
426 A Grimfeld (Egea1-2), J Just. Data and quality management: Inserm ex-U155 (Egea1): J Hochez;  
427 Inserm CESP/U 1018, Villejuif: N Le Moual, Inserm ex-U780: C Ravault (Egea1-2); Inserm ex-  
428 U794: N Chateigner; Grenoble: J Ferran (Egea1-2).

429 **SLSJ**: We thank all participants included in the SLSJ asthma familial collection. Catherine Laprise  
430 built, coordinates and manages the SLSJ study. Drs. Paul Bégin and Charles Morin confirmed the  
431 respiratory diagnosis for the adults and children respectively. We also thank the laboratory  
432 technician (Nadia Mior, Denise Morin), research professional (Anne-Marie Madore) and nurses  
433 (from the ECOGENE-21 Biocluster). Catherine Laprise is the Canada Research Chair in  
434 Environment and Genetics of Respiratory Disorders and Allergy, Director of the Asthma Strategic  
435 Group of the Respiratory Health Network (RHN) of Fonds de la recherche en santé du Québec  
436 (FRSQ) and researcher of the AllerGen NCE.

437 **MRC**: The authors thank all the families who participated and were recruited as part of the MRCA  
438 and MRCE collections (Coordination: M.F. Moffatt, W.O.C.M Cookson and J.I. Harper). We thank  
439 the research nurses involved as well as personnel who conducted blood extractions, IgE  
440 determinations and sample management (Anna Dixon). Genotyping of the cohorts was done by the  
441 CNG, Evry: I Gut (now CNAG, Barcelone, Spain), M Lathrop (now Univ McGill, Montreal,  
442 Canada).

443

444 **REFERENCES**

- 445 1. Ober C, Yao TC. The genetics of asthma and allergic disease: a 21st century perspective. *Immunol Rev*  
446 2011; 242:10-30.
- 447 2. Welter D, MacArthur J, Morales J, Burdett T, Hall P, Junkins H, *et al.* The NHGRI GWAS Catalog, a  
448 curated resource of SNP-trait associations. *Nucleic Acids Res* 2014; 42:D1001-6.
- 449 3. Bonnelykke K, Sparks R, Waage J, Milner JD. Genetics of allergy and allergic sensitization: common  
450 variants, rare mutations. *Curr Opin Immunol* 2015; 36:115-26.
- 451 4. Los H, Postmus PE, Boomsma DI. Asthma genetics and intermediate phenotypes: a review from twin  
452 studies. *Twin Res* 2001; 4:81-93.
- 453 5. Thomsen SF, Ulrik CS, Kyvik KO, Ferreira MA, Backer V. Multivariate genetic analysis of atopy  
454 phenotypes in a selected sample of twins. *Clin Exp Allergy* 2006; 36:1382-90.
- 455 6. Vercelli D. Discovering susceptibility genes for asthma and allergy. *Nat Rev Immunol* 2008; 8:169-82.
- 456 7. Andiappan AK, Wang de Y, Anantharaman R, Parate PN, Suri BK, Low HQ, *et al.* Genome-wide  
457 association study for atopy and allergic rhinitis in a Singapore Chinese population. *PLoS One* 2011;  
458 6:e19719.
- 459 8. Castro-Giner F, Bustamante M, Ramon Gonzalez J, Kogevinas M, Jarvis D, Heinrich J, *et al.* A  
460 pooling-based genome-wide analysis identifies new potential candidate genes for atopy in the European  
461 Community Respiratory Health Survey (ECRHS). *BMC Med Genet* 2009; 10:128.
- 462 9. Ramasamy A, Curjuric I, Coin LJ, Kumar A, McArdle WL, Imboden M, *et al.* A genome-wide meta-  
463 analysis of genetic variants associated with allergic rhinitis and grass sensitization and their interaction  
464 with birth order. *J Allergy Clin Immunol* 2011; 128:996-1005.
- 465 10. Wan YI, Strachan DP, Evans DM, Henderson J, McKeever T, Holloway JW, *et al.* A genome-wide  
466 association study to identify genetic determinants of atopy in subjects from the United Kingdom. *J*  
467 *Allergy Clin Immunol* 2011; 127:223-31, 31 e1-3.

- 468 11. Bonnelykke K, Matheson MC, Pers TH, Granell R, Strachan DP, Alves AC, *et al.* Meta-analysis of  
469 genome-wide association studies identifies ten loci influencing allergic sensitization. *Nat Genet* 2013;  
470 45:902-6.
- 471 12. Hinds DA, McMahon G, Kiefer AK, Do CB, Eriksson N, Evans DM, *et al.* A genome-wide association  
472 meta-analysis of self-reported allergy identifies shared and allergy-specific susceptibility loci. *Nat*  
473 *Genet* 2013; 45:907-11.
- 474 13. Dizier MH, Margaritte-Jeannin P, Madore AM, Esparza-Gordillo J, Moffatt M, Corda E, *et al.* The  
475 ANO3/MUC15 locus is associated with eczema in families ascertained through asthma. *J Allergy Clin*  
476 *Immunol* 2012; 129:1547-53 e3.
- 477 14. Sun X, Lu Q, Mukherjee S, Crane PK, Elston R, Ritchie MD. Analysis pipeline for the epistasis search  
478 - statistical versus biological filtering. *Front Genet* 2014; 5:106.
- 479 15. Li ZC, Huang MH, Zhong WQ, Liu ZQ, Xie Y, Dai Z, *et al.* Identification of drug-target interaction  
480 from interactome network with 'guilt-by-association' principle and topology features. *Bioinformatics*  
481 2016; 32:1057-64.
- 482 16. Luo Y, Riedlinger G, Szolovits P. Text mining in cancer gene and pathway prioritization. *Cancer*  
483 *Inform* 2014; 13:69-79.
- 484 17. Raychaudhuri S, Plenge RM, Rossin EJ, Ng AC, Purcell SM, Sklar P, *et al.* Identifying relationships  
485 among genomic disease regions: predicting genes at pathogenic SNP associations and rare deletions.  
486 *PLoS Genet* 2009; 5:e1000534.
- 487 18. Kauffmann F, Dizier MH, Annesi-Maesano I, Bousquet J, Charpin D, Demenais F, *et al.* EGEA  
488 (Epidemiological study on the Genetics and Environment of Asthma, bronchial hyperresponsiveness  
489 and atopy)-- descriptive characteristics. *Clin Exp Allergy* 1999; 29 Suppl 4:17-21.
- 490 19. Kaufmann F, Dizier MH, Pin I, Paty E, Gormand F, Vervloet D, *et al.* Epidemiological Study of the  
491 Genetics and Environment of Asthma, Bronchial Hyperresponsiveness, and Atopy. *Am J Respir Crit*  
492 *Care Med* 1997; 156:123-9.

- 493 20. Bouzigon E, Nadif R, Le Moual N, Dizier MH, Aschard H, Boudier A, *et al.* [Genetic and  
494 environmental factors of asthma and allergy: Results of the EGEA study]. *Rev Mal Respir* 2015;  
495 32:822-40.
- 496 21. Laprise C. The Saguenay-Lac-Saint-Jean asthma familial collection: the genetics of asthma in a young  
497 founder population. *Genes Immun* 2014; 15:247-55.
- 498 22. Moffatt MF, Kabesch M, Liang L, Dixon AL, Strachan D, Heath S, *et al.* Genetic variants regulating  
499 ORMDL3 expression contribute to the risk of childhood asthma. *Nature* 2007; 448:470-3.
- 500 23. Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, *et al.* A large-scale, consortium-  
501 based genomewide association study of asthma. *N Engl J Med* 2010; 363:1211-21.
- 502 24. Sarnowski C, Sugier PE, Granell R, Jarvis D, Dizier MH, Ege M, *et al.* Identification of a new locus at  
503 16q12 associated with time to asthma onset. *J Allergy Clin Immunol* 2016.
- 504 25. Liang L, Morar N, Dixon AL, Lathrop GM, Abecasis GR, Moffatt MF, *et al.* A cross-platform analysis  
505 of 14,177 expression quantitative trait loci derived from lymphoblastoid cell lines. *Genome Res* 2013;  
506 23:716-26.
- 507 26. Li Y, Abecasis GR. Mach 1.0: Rapid haplotype reconstruction and missing genotype inference. *Am. J.*  
508 *Hum. Genet.* 2006; S79:2290.
- 509 27. Li Y, Willer C, Sanna S, Abecasis G. Genotype imputation. *Annu Rev Genomics Hum Genet* 2009;  
510 10:387-406.
- 511 28. Li MX, Yeung JM, Cherny SS, Sham PC. Evaluating the effective numbers of independent tests and  
512 significant p-value thresholds in commercial genotyping arrays and public imputation reference  
513 datasets. *Hum Genet* 2012; 131:747-56.
- 514 29. Herold C, Steffens M, Brockschmidt FF, Baur MP, Becker T. INTERSNP: genome-wide interaction  
515 analysis guided by a priori information. *Bioinformatics* 2009; 25:3275-81.
- 516 30. Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation  
517 matrix. *Heredity* 2005; 95:221-7.
- 518 31. Cochran WG. The comparison of percentages in matched samples. *Biometrika* 1950; 37:256-66.



- 519 32. The GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis:  
520 multitissue gene regulation in humans. *Science* 2015; 348:648-60.
- 521 33. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory  
522 motif alterations within sets of genetically linked variants. *Nucleic Acids Res* 2012; 40:D930-4.
- 523 34. Fliegauf M, Benzing T, Omran H. When cilia go bad: cilia defects and ciliopathies. *Nat Rev Mol Cell*  
524 *Biol* 2007; 8:880-93.
- 525 35. Weston MD, Luijendijk MW, Humphrey KD, Moller C, Kimberling WJ. Mutations in the VLGR1  
526 gene implicate G-protein signaling in the pathogenesis of Usher syndrome type II. *Am J Hum Genet*  
527 2004; 74:357-66.
- 528 36. Besnard T, Vache C, Baux D, Larrieu L, Abadie C, Blanchet C, *et al.* Non-USH2A mutations in USH2  
529 patients. *Hum Mutat* 2012; 33:504-10.
- 530 37. Leigh MW, Zariwala MA, Knowles MR. Primary ciliary dyskinesia: improving the diagnostic  
531 approach. *Curr Opin Pediatr* 2009; 21:320-5.
- 532 38. Olbrich H, Horvath J, Fekete A, Loges NT, Storm van's Gravesande K, Blum A, *et al.* Axonemal  
533 localization of the dynein component DNAH5 is not altered in secondary ciliary dyskinesia. *Pediatr*  
534 *Res* 2006; 59:418-22.
- 535 39. Armengot M, Salom D, Diaz-Llopis M, Millan JM, Milara J, Mata M, *et al.* Nasal ciliary beat frequency  
536 and beat pattern in retinal ciliopathies. *Invest Ophthalmol Vis Sci* 2012; 53:2076-9.
- 537 40. Bonneau D, Raymond F, Kremer C, Klossek JM, Kaplan J, Patte F. Usher syndrome type I associated  
538 with bronchiectasis and immotile nasal cilia in two brothers. *J Med Genet* 1993; 30:253-4.
- 539 41. Lee JH, McDonald ML, Cho MH, Wan ES, Castaldi PJ, Hunninghake GM, *et al.* DNAH5 is associated  
540 with total lung capacity in chronic obstructive pulmonary disease. *Respir Res* 2014; 15:97.
- 541 42. Kovacic MB, Myers JM, Wang N, Martin LJ, Lindsey M, Ericksen MB, *et al.* Identification of KIF3A  
542 as a novel candidate gene for childhood asthma using RNA expression and population allelic  
543 frequencies differences. *PLoS One* 2011; 6:e23714.

- 544 43. Dizier MH, Nadif R, Margaritte-Jeannin P, Barton SJ, Sarnowski C, Gagne-Ouellet V, *et al.* Interaction  
545 between the DNAH9 gene and early smoke exposure in bronchial hyperresponsiveness. *Eur Respir J*  
546 2016; 47:1072-81.
- 547 44. Almoguera B, Vazquez L, Mentch F, Connolly J, Pacheco JA, Sundaresan AS, *et al.* Identification of  
548 Four Novel Loci in Asthma in European and African American Populations. *Am J Respir Crit Care*  
549 *Med* 2016 Sep 9; [Epub ahead of print].
- 550 45. Jones AC, Troy NM, White E, Hollams EM, Gout AM, Ling KM, *et al.* Persistent activation of  
551 interlinked Th2-airway epithelial gene networks in sputum-derived cells from aeroallergen-sensitized  
552 symptomatic atopic asthmatics. *bioRxiv* 2016; <https://doi.org/10.1101/063602>
- 553

**Table I.** *ADGRV1* locus on 5q14 showing significant association with atopy

SNP	Position (kb)*	Alleles†	MAF‡	Stage 1		Stage 2						Overall Meta-Analysis		
				EGEA (N=1,660)		SLSJ (N=1,138)		MRC (N=446)		Meta-Analysis		beta (se) §	$P_{meta}^{\dagger\dagger}$	$P_{Cochran}^{\ddagger\dagger}$
				beta (se) §	$P^{\parallel}$	beta (se) §	$P^{\parallel}$	beta (se) §	$P^{\parallel}$	beta (se) §	$P_{stage2}^{**}$			
rs4244205	90,188	A/G	0.41	-0.35 (0.08)	$1.1 \times 10^{-5}$	-0.19 (0.10)	$6.0 \times 10^{-2}$	-0.14 (0.18)	0.45	-0.18 (0.09)	$4.4 \times 10^{-2}$	-0.27 (0.06)	$3.8 \times 10^{-6}$	0.35
rs4916831	90,212	A/G	0.44	-0.40 (0.08)	$1.0 \times 10^{-6}$	-0.32 (0.11)	$2.3 \times 10^{-3}$	-0.21 (0.17)	0.23	-0.29 (0.09)	$1.2 \times 10^{-3}$	-0.35 (0.06)	<b><math>6.8 \times 10^{-9}</math></b>	0.59
rs10060641	90,213	T/C	0.38	-0.39 (0.08)	$7.2 \times 10^{-7}$	-0.17 (0.11)	0.11	-0.24 (0.19)	0.22	-0.18 (0.09)	$4.8 \times 10^{-2}$	-0.30 (0.06)	$4.3 \times 10^{-7}$	0.23
rs12054681	90,217	C/A	0.37	-0.39 (0.08)	$9.7 \times 10^{-7}$	-0.14 (0.11)	0.18	-0.29 (0.21)	0.16	-0.17 (0.09)	$6.5 \times 10^{-2}$	-0.30 (0.06)	$7.8 \times 10^{-7}$	0.18
rs949787	90,251	G/T	0.28	-0.33 (0.08)	$5.5 \times 10^{-5}$	-0.23 (0.10)	$2.0 \times 10^{-2}$	-0.19 (0.20)	0.36	-0.22 (0.09)	$1.2 \times 10^{-2}$	-0.28 (0.06)	$3.2 \times 10^{-6}$	0.65

\*Position in kilobases (kb) according to NCBI dbSNP Build 137

†Major allele/Minor allele

‡Minor allele frequency

§beta is the regression coefficient for a one-unit increase of the effect allele in logistic regression assuming an additive model; se is the standard error associated with the regression coefficient.

∥ $P$  is the  $P$ -value associated with the Wald test of SNP effect.

\*\* $P_{stage2}$  is the  $P$ -values associated with the Wald test of meta-analyzed SNP effect in the stage 2 datasets (SLSJ and MRC).

†† $P_{meta}$  is the  $P$ -value associated with the Wald test of meta-analyzed SNP effect in the three datasets (EGEA, SLSJ, MRC); the  $P$ -value is shown in bold when it reached the multiple-testing corrected threshold of  $1.5 \times 10^{-7}$ .

‡‡ $P_{Cochran}$  is the  $P$ -value associated with Cochran's Q test of homogeneity across the three datasets.

**Table II.** SNP pairs showing significant interaction for atopy

SNPs	Chr*	Genes†	Alleles‡	MAF§	Stage 1			Stage 2						Overall Meta-analysis						
					EGEA (N=1,660)			SLSJ (N=1,138)			MRC (N=446)			Meta-Analysis			Main effect		Interaction	
					Main effect	Interaction		Main effect	Interaction		Main effect	Interaction		Main effect	Interaction		Main effect	Interaction		
					beta (se)¶	beta (se)¶	P <sub>int</sub> **	beta (se)¶	beta (se)¶	P <sub>int</sub> **	beta (se)¶	beta (se)¶	P <sub>int</sub> **	beta (se)¶	beta (se)¶	P <sub>stage2-int</sub> ††	beta (se)¶	beta (se)¶	P <sub>meta-int</sub> ‡‡	P <sub>Cochran</sub> §§
rs17554723	5	<i>ADGRV1</i>	A/G	0.33	-0.06 (0.10)	-0.38 (0.12)	3.0x10 <sup>-3</sup>	0.02 (0.13)	-0.42 (0.16)	1.1x10 <sup>-2</sup>	0.13 (0.23)	-0.28 (0.33)	0.40	0.04 (0.11)	-0.39 (0.14)	6.1x10 <sup>-3</sup>	-0.02 (0.08)	-0.38 (0.09)	<b>3.6x10<sup>-5</sup></b>	0.84
rs2134256¶¶	5	<i>DNAH5</i>	T/C	0.25	0.13 (0.09)			-0.06 (0.13)			0.03 (0.26)			-0.04 (0.12)			0.06 (0.07)			
rs17554723	5	<i>ADGRV1</i>	A/G	0.33	0.03 (0.09)	-0.34 (0.11)	3.3x10 <sup>-3</sup>	0.13 (0.11)	-0.35 (0.14)	1.4x10 <sup>-2</sup>	0.19 (0.21)	-0.16 (0.29)	0.59	0.14 (0.10)	-0.32 (0.12)	9.3x10 <sup>-3</sup>	0.08 (0.06)	-0.33 (0.08)	<b>6.1x10<sup>-5</sup></b>	0.92
rs1354187¶¶	5	<i>DNAH5</i>	T/C	0.36	0.08 (0.08)			-0.04 (0.11)			0.05 (0.22)			-0.02 (0.10)			0.04 (0.06)			

\*Chr is the chromosome number where the SNP is located

†Gene symbol of gene where SNP lies

‡Major allele/Minor allele

§Minor allele frequency

¶beta for the main effect is the regression coefficient for a one-unit increase of the effect allele in logistic regression assuming an additive model; beta for interaction is the regression coefficient for homozygotes for the minor allele at the two loci or homozygotes for the major allele at the two loci with respect to heterozygotes at either one or the two loci using the coding scheme under an additive genetic model described in the methods section; se is the standard error associated with the regression coefficient.

\*\*P<sub>int</sub> is the P-value of the likelihood-ratio test for interaction between SNPs (which follows a chi-square distribution with one degree of freedom assuming an additive model).

††P<sub>stage2-int</sub> is the P-values associated with the Wald test of meta-analyzed interaction effect in the stage 2 datasets (SLSJ and MRC).

‡‡P<sub>meta-int</sub> is the P-values associated with the Wald test of meta-analyzed interaction effect in the three datasets (EGEA, SLSJ, MRC); P<sub>meta-int</sub> is shown in bold when it reached the multiple-testing corrected threshold of 7.3x10<sup>-5</sup>.

§§P<sub>Cochran</sub> is the P-value associated with Cochran's Q test of homogeneity across the three datasets.

¶¶The two *DNAH5* SNPs, rs1354187 and rs2134256, showing significant interaction with *ADGRV1* SNP are in moderate linkage disequilibrium (r<sup>2</sup>=0.50; D'=0.95).

## FIGURE LEGENDS

**Figure 1.** Three-step analysis strategy

**Figure 2.** Odds-ratio (ORs) and 95% confidence intervals for atopy associated with each genotype at *DNAH5* rs2134256 (TT, CT, CC) in each of the strata defined by genotypes at *ADGRV1* rs17554723 (AA, AG, or GG). These ORs were calculated using the genotype coding scheme defined in the text and are shown for each of the three datasets (EGEA, SLSJ, MRC) and for the combined dataset.

Figure 1.




Figure 2.

